News
CGTX
0.6006
+0.10%
0.0006
Cognition Therapeutics: Zervimesine’s Favorable Profile and Phase 3 Dementia with Lewy Bodies Trial Support $3 Price Target
TipRanks · 1d ago
We're Not Very Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
Simply Wall St · 1d ago
Weekly Report: what happened at CGTX last week (1109-1113)?
Weekly Report · 4d ago
Cognition Therapeutics Earnings Call Signals DLB Momentum
TipRanks · 5d ago
What Makes Cognition Therapeutics (CGTX) a New Buy Stock
NASDAQ · 11/10 19:43
Cognition Therapeutics: Buy Reiterated on Zervimesine’s Phase 3 Progress; $3 Price Target Unchanged
TipRanks · 11/09 12:15
Weekly Report: what happened at CGTX last week (1102-1106)?
Weekly Report · 11/09 09:44
Cognition's Q3 Loss Declines To $4 Mln As Phase 3 For Zervimesine In Dementia Set To Begin
NASDAQ · 11/07 14:26
Cognition Therapeutics (CGTX) Receives a New Rating from B. Riley Securities
TipRanks · 11/06 14:35
Cognition Tx (CGTX) Q3 2026 Earnings Call Transcript
NASDAQ · 11/05 20:45
Cognition Therapeutics, Inc. Receives Nasdaq Deficiency Letter and Reports Third Quarter 2026 Financial Results
NASDAQ · 11/05 11:52
Cognition Therapeutics Reports Third-Quarter Results, Advances Zervimesine Program
TipRanks · 11/05 11:39
Cognition Therapeutics GAAP EPS of -$0.04 beats by $0.03
Seeking Alpha · 11/05 11:22
Cognition Therapeutics reports Q3 EPS (4c), consensus (7c)
TipRanks · 11/05 11:10
*Cognition Therapeutics: Cash, Cash Equivalents, and Restricted Cash Equivalents as of Sept 30 Were About $31.5M >CGTX
Dow Jones · 11/05 11:08
*Cognition Therapeutics: Estimate Have Sufficient Cash to Fund Ops and Cap Expenditures Into the 4Q of 2027 >CGTX
Dow Jones · 11/05 11:08
*Cognition Therapeutics 3Q Loss/Shr 4c >CGTX
Dow Jones · 11/05 11:07
Cognition Therapeutics Q3 EPS $(0.04) Beats $(0.07) Estimate
Benzinga · 11/05 11:03
Press Release: Cognition Therapeutics Reports -2-
Dow Jones · 11/05 11:01
Press Release: Cognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business Update
Dow Jones · 11/05 11:01
More
Webull provides a variety of real-time CGTX stock news. You can receive the latest news about COGNITION THERAPEUTICS INC through multiple platforms. This information may help you make smarter investment decisions.
About CGTX
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. The Company is investigating its lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer’s disease. Its CT1812 and pipeline of sigma-2 modulators can regulate pathways that are impaired in these diseases for the treatment of degenerative diseases. Its lead product candidate, CT1812, is an orally delivered, small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins. Its pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways. It is developing other product candidates in the area of synucleinopathies.